Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Optimize the Dosing Regimen and Assess Safety and Efficacy of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus

NCT05757544 is registered in ClinicalTrials.gov with Marinus Pharmaceuticals as lead sponsor.

NCT NCT05757544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05757544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Optimize the Dosing Regimen and Assess Safety and Efficacy of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus
Lead sponsor
Marinus Pharmaceuticals
Phase
Phase 2
Overall status
Withdrawn
Start date
April 1, 2023
Completion date
February 28, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

status epilepticus